Article

Zinc blend available

OCuSOFT Inc.'s proprietary blend of zinc and phytase (Zytaze) is now available for physician dispensing. This proprietary medical food is designed to provide nutritional support to enhance the effectiveness of botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, or cosmetic procedures.

Richmond, TX-OCuSOFTInc.’s proprietary blend of zinc and phytase (Zytaze) is now available for physician dispensing.

This medical food is designed to provide nutritional support to enhance the effectiveness of botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, or cosmetic procedures.

The blend is one of organic zinc and phytase, an enzyme that aids zinc absorption and increases bioavailability. According to OCuSOFT, increasing zinc bioavailability is important because, to be effective, each botulinum toxin molecule must be associated with a zinc molecule, yet many patients’ diets are zinc-deficient.

Taking the zinc and phytase blend each day for 4 days before and on the day of an injection may increase both the effect of treatments and the duration of botulinum toxin, and could mean using less toxin, financial savings, increased safety, and more consistent botulinum toxin results for many patients, according to OCuSOFT.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.